Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China.

A growing economy, large population base, and innovation-friendly environment are other key parameters that are anticipated to drive the growth of the pharmaceutical contract manufacturing market in China. Further, in order to meet the growing demand for their services, CMOs having manufacturing facilities in China are actively expanding their existing capacities and capabilities in the region.

To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

The USD 13 billion (by 2030) financial opportunity within the pharmaceuticals contract manufacturing market in China has been analyzed across the following segments:
 Key Geographical Regions
 Eastern China
 Southern China
 Northern China

 Type of Product
 Active Pharmaceutical Ingredients (APIs)
 Drug Products

 Type of Drug Product
 Solid
 Liquid / Semi-Solid
 Injectable
 Others

 Scale of Operation
 Clinical
 Commercial

 Company Size
 Small
 Mid-Sized
 Large / Very Large

The China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”
report features the following companies, which we identified to be key players in this domain:
 2Y-Chem
 Aurisco Pharmaceutical
 ChemPartner
 Dorrapharma
 Hubei Biocause Pharmaceutical
 Infoark
 Ningbo Menovo Pharmaceutical
 Shandong Xinhua Pharmaceutical
 Shanghai Acebright Pharmaceuticals
 STA Pharmaceutical
 Zhejiang Huahai Pharmaceutical

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Case Study: Comparison of Small Molecules and Large Molecules

5. Market Overview

6. Manufacturing Facilities of Pharmaceutical CMOs in China

7. Pharmaceutical Manufacturing Regulations in China

8. Company Profiles

9. Big Pharma Initiatives in China

10. Recent Trends

11. Capacity Analysis

12. SWOT Analysis

13. Market Forecast

14. Case Study: Impact of Coronavirus Outbreak

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com